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Abstract
Background: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace
in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy
contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle.
Methods: A cross-sectional survey was carried out between April 2007 and October 2007 at Yamanashi Prefectural
KITA hospital in Japan. 334 patients consented to this cross-sectional study. We measured the components
consisting metabolic syndrome, and interviewed the participants about their lifestyle. We classified metabolic
syndrome into four groups according to the severity of metabolic disturbance: the metabolic syndrome; the pre-
metabolic syndrome; the visceral fat obesity; and the normal group. We used multinomial logistic regression
models to assess the association of metabolic syndrome with antipsychotic polypharmacy, adjusting for lifestyle.
Results: Seventy-four (22.2%) patients were in the metabolic syndrome group, 61 (18.3%) patients were in the pre-
metabolic syndrome group, and 41 (12.3%) patients were in visceral fat obesity group. Antipsychotic polypharmacy
was present in 167 (50.0%) patients. In multinomial logistic regression analyses, antipsychotic polypharmacy was
significantly associated with the pre-metabolic syndrome group (adjusted odds ratio [AOR], 2.348; 95% confidence
interval [CI], 1.181-4.668), but not with the metabolic syndrome group (AOR, 1.269; 95%CI, 0.679-2.371).
Conclusions: These results suggest that antipsychotic polypharmacy, compared with monotherapy, may be
independently associated with an increased risk of having pre-metabolic syndrome, even after adjusting for
patients’ lifestyle characteristics. As metabolic syndrome is associated with an increased risk of cardiovascular
mortality, further studies are needed to clarify the validity and safety of antipsychotic polypharmacy.
Background
Metabolic syndrome is a cluster of metabolic dysfunctions,
including central obesity, hypertension, glucose, and lipid
abnormalities. Those with the syndrome have a two- to
threefold increase in cardiovascular mortality and a two-
fold increase in all-cause mortality [1]. Patients with schi-
zophrenia are more likely to have metabolic syndrome
than the general population [2].
To date, a few research studies have reported an asso-
ciation between antipsychotic polypharmacy and
metabolic syndrome [3,4]. Limited evidence currently
exists regarding the benefits of antipsychotic polyphar-
macy, and antipsychotic monotherapy is consistently
recommended in the treatment of patients with schizo-
phrenia [5,6]. Antipsychotic polypharmacy is, however,
commonplace in the treatment of schizophrenia [7-11],
and has been reported to occur in a wide range (13-
90%) of cases. In Japan, in particular, polypharmacy has
been reported to occur at a higher rate than in other
countries [12].
If antipsychotic polypharmacy, which is not recom-
mended, is associated with a greater risk of metabolic syn-
drome, the spread of polypharmacy is a serious concern.
However, it remains unclear among earlier studies
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whether antipsychotic polypharmacy is associated with
metabolic syndrome as a direct result of patients’
unhealthy lifestyle. Patients with schizophrenia are likely
to make poor dietary choices, have low rates of physical
activity, and smoke cigarettes [13], and their unhealthy
lifestyle is assumed to be associated with an increased risk
of metabolic syndrome. However, as little information is
available on the association between metabolic syndrome
and antipsychotic polypharmacy in conjunction with
patients’ lifestyle, further research is needed any such
association.
In this cross-sectional study, we aimed to investigate
the relationships between antipsychotic polypharmacy
and metabolic syndrome in outpatients with schizophre-
nia, with adjustment for the effects of lifestyle.
Methods
Study participants
Participants who lived in the community and received
psychiatric outpatient treatment were recruited from
April 2007 to October 2007. The study inclusion criteria
were: regular attendance at Yamanashi Prefectural KITA
Hospital, Japan; an ICD-10 diagnosis of schizophrenia,
schizotypal and delusional disorders; and age 18 years or
older.
During the study period, of all 599 patients who ful-
filled the inclusion criteria in this study, 399 consented
to participate in the study. As 65 of these patients did
not complete the questionnaire, data from 334 patients
were used in the analysis.
The study design was approved by the Ethics Commit-
tees of Yamanashi Prefectural KITA Hospital. Written
informed consent was obtained from all participants.
Assessment
Assessment in this study consisted of sociodemographics
(age, gender), duration of psychiatric treatment, family
history of lifestyle-related disease, metabolic syndrome,
prescribed antipsychotics, and participants’ lifestyle. In
addition, psychiatrists in charge of the participants
assessed the patients on the Global Assessment of Func-
tioning (GAF) scale.
Metabolic syndrome
Rather than using the discrete diagnostic category of
metabolic syndrome, we divided metabolic syndrome
into four groups based on severity of metabolic distur-
bance (metabolic syndrome, pre-metabolic syndrome,
visceral fat obesity and normal), since metabolic
syndrome is continuously disturbed in nature [14]. In
accordance with the diagnostic criteria proposed by the
Japanese Committee of the Metabolic Syndrome Diag-
nostic Criteria [15], metabolic syndrome was defined as
visceral fat obesity (abdominal circumference: ≥85 cm for
males, ≥90 cm for females) and at least two of the follow-
ing three criteria: elevated blood glucose (fasting glucose
level ≥110 mg/dL), lipid abnormalities (triglycerides ≥150
mg/dL and/or high-density lipoprotein (HDL) cholesterol
<40 mg/dL), and elevated blood pressure (systolic blood
pressure ≥130 mmHg and/or diastolic blood pressure
≥85 mmHg). Current treatment with diabetes, lipid-
lowering, or antihypertensive medication fulfilled the cri-
terion for elevated blood glucose, lipid abnormality, and
elevated blood pressure, respectively. Pre-metabolic syn-
drome was defined as the presence of one of the above
three criteria in addition to visceral fat obesity.
We classified metabolic syndrome in the following
four groups: the normal group did not fulfill the criteria
of visceral fat obesity, the visceral fat obesity group ful-
filled only the criteria of visceral fat obesity, the pre-
metabolic syndrome group was defined by the presence
of only one of the three criteria above in addition to
visceral fat obesity, and the metabolic syndrome group
was defined by the presence of at least two of the three
criteria above in addition to visceral fat obesity. Partici-
pants were given written instructions to fast overnight
on the day before assessment, and asked to confirm
their fasting status before blood samples were taken. A
single venous blood sample was withdrawn and analyzed
for glucose, triglycerides, and HDL cholesterol. Nurses
measured abdominal circumference and blood pressure.
Prescribed antipsychotics
We investigated prescribed antipsychotics from patient
charts on the day we measured the participant’s meta-
bolic syndrome parameters. All dosages of antipsychotic
drugs were converted into chlorpromazine equivalents
[16] in order to estimate the total daily chlorpromazine-
equivalent dose.
In this study, polypharmacy was defined as the concomi-
tant use of two or more antipsychotics, while monother-
apy was defined as the use of only one antipsychotic.
Antipsychotic treatment in Japan was subject to special
conditions during the study period. First, clozapine had
not been launched at this time. Second, olanzapine and
quetiapine were contraindicated for patients with dia-
betes or a history of diabetes because it was reported that
some patients that were treated with olanzapine and que-
tiapine developed severe hyperglycemia and diabetic
coma.
Assessment of participants’ lifestyle
We assessed the participants’ dietary habits, physical
activity, and smoking habits. With regards to dietary
habits, these were assessed by an originally designed self-
reporting questionnaire that consisted of the following
four items, which have been used in earlier studies: snack
eating (Do you eat snacks?), intake of fatty foods (Do you
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eat fatty foods?), preference for a high-salt diet (Do you
put soy sauce or Worcestershire sauce on your food?),
and consumption of soft drinks (Do you drink soft
drinks?) [17,18]. Each item was scored on a 4-point scale
(1 = never, 2 = rarely, 3 = sometimes, 4 = always).
To assess the participants’ physical activity, we used
the Exercise and Physical Activity Guide for Health Pro-
motion 2006 [19]. In this guide, physical activity consists
of exercise and non-exercise activities (e.g., walking,
cleaning the floors, and walking up and down stairs).
The units used to express the intensity and quantity of
physical activity are “MET” and “MET × hour”, respec-
tively. MET is calculated as energy expenditure (oxygen
uptake, mL/kg/min) during a specific physical activity
divided by sitting/resting energy expenditure. Defining
the MET of sitting/resting as 1, that of normal walking,
for example, is 3. The unit “MET × hour” (expressed as
“Ex” for Exercise (Ekusasaizu in Japanese)) was calcu-
lated by multiplying the MET by the duration of the
activity (hour). The goal for physical activity was set at
23 Ex or more per week, with 3 MET of physical activity
set as the minimum (cut off).
Using the Compendium of Physical Activities [19], we
interviewed participants about their exercise and non-
exercise activities with more than 3 MET in the one
week prior to the study day, and calculated the quantity
of their physical activity.
Participants’ smoking habits were rated as 1 (= 21 or
more cigarettes per day), 2 (= 6 to 20), 3 (= 1 to 5), or 4
(= no cigarette).
Data analyses
Analyses of variance, chi-square tests, and Kruskal-Wallis
tests were used to compare demographic, treatment and
clinical variables in the classification of metabolic
syndrome.
To examine the effects of antipsychotic polypharmacy
on metabolic syndrome, we conducted multinomial
logistic regression analyses, with the classification of
metabolic syndrome as the dependent variable. For the
analyses, we entered the variables whose p-values were
less than 0.1 in univariate tests into the model. A p
value of <0.05 was considered statistically significant.
Data were analyzed using SPSS 14.0 J for Windows.
Results
Characteristics, lifestyle, and antipsychotic treatment of
participants (Table 1)
The mean age of the 334 participants was 44.2 years,
and 42.8% were female. The mean GAF score was 53.5,
48.8% had a family history of lifestyle-related disease,
and the mean duration of psychiatric treatment was 18.2
years. The mean value of physical activity was 22.4 Ex,
and the mean score for smoking habit was 3.0.
The mean dose in chlorpromazine equivalents was 596.6
mg/day, and 35.0% received olanzapine and quetiapine.
One hundred six (31.7%) patients received two antipsycho-
tics, 48 (14.4%) patients were on three antipsychotics, and
13 (3.9%) patients were on four antipsychotics. According
to the definition in this study that polypharmacy was
the concomitant use of two or more antipsychotics, 167
participants (50.0%) were receiving antipsychotic
polypharmacy.
Category of metabolic syndrome
Of the 334 participants, 176 (52.7%) fulfilled the visceral
fat obesity criteria, 92 (27.5%) fulfilled the elevated blood
glucose criteria, 138 (41.3%) fulfilled the lipid abnormality
criteria, and 105 (31.4%) fulfilled the elevated blood pres-
sure criteria. Seventy-four (22.2%) patients were in the
metabolic syndrome group, 61 (18.3%) patients were in
the pre-metabolic syndrome group, 41 (12.3%) patients
were in the visceral fat obesity group, and 158 (47.3%)
were in the normal group. The characteristics, lifestyle and
antipsychotic treatment in each group are summarized in
Table 1. The rate of polypharmacy in the groups of meta-
bolic syndrome, pre-metabolic syndrome, visceral fat obe-
sity and normal were 52.7%, 63.9%, 61.0%, and 40.5%,
respectively.
Compared to the monotherapy group, the polyphar-
macy group was more likely to fulfil the visceral fat obe-
sity criterion (61.7% vs. 43.7%, p = 0.0014) and the
elevated blood glucose criterion (32.9% vs. 22.2%, p =
0.037), and less likely to fulfil the elevated blood pressure
criterion (26.3% vs. 36.5%, p = 0.045). The prevalence of
the metabolic syndrome group in monotherapy and poly-
pharmacy showed no significant difference (23.4% vs.
21.0%, p = 0.60). However, the polypharmacy group was
more likely to be the pre-metabolic syndrome group
(46.7% vs. 34.1%, p = 0.019).
Multinomial logistic regression analyses (Table 2)
Multinomial logistic regression analyses revealed that
the metabolic syndrome group was associated with
being male, longer duration of psychiatric treatment,
and heavier smoking habit. The pre-metabolic syndrome
group was associated with being male and antipsychotic
polypharmacy. The visceral fat obesity group was asso-
ciated with being male and higher antipsychotic total
daily dose.
Thus, overall, antipsychotic polypharmacy was not
related to the severity of symptoms in the metabolic
syndrome group but was related to the severity of symp-
toms in the pre-metabolic syndrome group.
Discussion
Our study shows that antipsychotic polypharmacy is not
correlated with metabolic syndrome but is correlated
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with the wider range of the syndrome when adjusting
for the effects of lifestyle in outpatients with schizophre-
nia. These findings indicate that antipsychotic polyphar-
macy contributes in part to metabolic syndrome.
It remains unclear why antipsychotic polypharmacy is
correlated with metabolic disturbance. Earlier studies sug-
gested that various receptors effects, such as H1, D2, 5-
HT1A, 5-HT2C, a2, and M3, might contribute to metabolic
disturbance [20]. We speculate that the complex receptor-
binding profiles of antipsychotic polypharmacy might be
one of the causes of metabolic disturbance.
Among earlier studies, the association between meta-
bolic syndrome and antipsychotic polypharmacy was not
certain. For example, Correll et al. [3] observed that
patients who receive antipsychotic polypharmacy had
significantly higher rates of metabolic syndrome in













Age, mean (SD), y 44.2 (12.3) 43.5 (13.2) 42.4 (11.4) 43.4 (12.2) 47.2 (10.6) 0.11
Female, % (n) 42.8 (143) 62.7 (99) 22.0 (9) 21.3 (13) 29.7% (22) <0.01
GAF, mean (SD) 53.5 (15.3) 54.6 (15.0) 51.3 (15.5) 53.3 (15.6) 52.5 (15.6) 0.58
Family history, % (n) 48.8 (163) 48.7 (77) 48.8 (20) 44.3 (27) 52.7 (39) 0.81
Duration of psychiatric treatment, mean
(SD), y
18.2 (12.1) 16.8 (12.2) 18.7 (11.8) 17.2 (11.3) 21.5 (12.1) 0.04
Lifestyle
Snacks eating, % (n) 0.39
1 = never 12.9 (43) 13.3 (21) 9.8 (4) 13.1 (8) 13.5 (10)
2 = rarely 26.9 (90) 28.5 (45) 24.4 (10) 27.9 (17) 24.3 (18)
3 = sometimes 40.7 (136) 39.2 (62) 31.7 (13) 41.0 (25) 48.6 (36)
4 = always 19.5 (65) 19.0 (30) 34.1 (14) 18.0 (11) 13.5 (10)
Fatty foods, % (n) 0.18
1 = never 2.4 (8) 5.1 (8) 0.0 (0) 0.0 (0) 0.0 (0)
2 = rarely 21.6 (72) 23.4 (37) 17.1 (7) 23.0 (14) 18.9 (14)
3 = sometimes 59.0 (197) 57.0 (90) 65.9 (27) 59.0 (36) 59.5 (44)
4 = always 17.1 (57) 14.6 (23) 17.1 (7) 18.0 (11) 21.6 (16)
High salt diet, % (n) 0.77
1 = never 4.5 (15) 3.2 (5) 1.6 (1) 1.6 (1) 10.8 (8)
2 = rarely 20.1 (67) 22.2 (35) 19.5 (8) 19.7 (12) 16.2 (12)
3 = sometimes 42.2 (141) 43.0 (68) 36.6 (15) 50.8 (31) 36.5 (27)
4 = always 33.2 (111) 31.6 (50) 41.5 (17) 27.9 (17) 36.5 (27)
Consumption of soft drink, % (n) 0.16
1 = never 11.1 (37) 13.3 (21) 9.8 (4) 11.5 (7) 6.8 (5)
2 = rarely 21.6 (72) 26.6 (42) 29.3 (12) 9.8 (6) 16.2 (12)
3 = sometimes 41.9 (140) 36.7 (58) 29.3 (12) 49.2 (30) 54.1 (40)
4 = always 25.4 (85) 23.4 (37) 31.7 (13) 29.5 (18) 23.0 (17)
Smoking habit, per day, % (n) <0.01
1 = 21 or more 18.6 (62) 13.9 (22) 7.3 (3) 24.6 (15) 29.7 (22)
2 = 6 to 20 21.6 (72) 17.7 (28) 26.8 (11) 24.6 (15) 24.3 (18)
3 = 1 to 5 3.9 (13) 5.1 (8) 2.4 (1) 3.3 (2) 2.7 (2)
4 = none 56.0 (187) 63.3 (100) 63.4 (26) 47.5 (29) 43.2 (32)
Physical activity, mean (SD), Ex 22.4 (37.3) 21.0 (38.1) 17.9 (19.5) 30.0 (51.9) 21.7 (27.3) 0.34
Antipsychotic treatment
Total daily dose, mean (SD), mg/d 596.6 (453.4) 510.3 (419.6) 769.2 (437.6) 668.4 (452.3) 626.2 (497.9) <0.01
Antipsychotics contraindicated for
diabetes, % (n)
35.0 (117) 62.7 (99) 65.9 (27) 63.9 (39) 56.8 (42) 0.74
Antipsychotic polypharmacy, % (n) 50.0 (167) 40.5 (64) 61.0 (25) 63.9 (39) 52.7 (39) 0.01
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univariate analyses, but antipsychotic polypharmacy was
not independently associated with metabolic syndrome
in logistic regression analyses which accounted for
demographic and clinical variables. They speculated that
antipsychotic polypharmacy was not a primary factor for
metabolic syndrome, and that factors related to antipsy-
chotic polypharmacy, such as inactivity, contributed to
the risk of metabolic syndrome.
Physical activity was not associated with metabolic
syndrome of any severity in this study. We infer that the
association between metabolic syndrome and antipsy-
chotic polypharmacy is not certain because of the effect
of antipsychotic polypharmacy on lowering blood pres-
sure, rather than because of the effect of inactivity. It
was reported that polypharmacy was associated with a
significantly higher drop in systolic pressure than mono-
therapy [21]. This might be due to the effects of a
higher dose than that received during monotherapy or a
drug interaction which created dopaminergic and nora-
drenergic deficiency conditions, such as Shy-Drager syn-
drome. Similarly, in the present study, patients receiving
antipsychotic polypharmacy were less likely to fulfil the
criterion of elevated blood pressure. Consequently,
because antipsychotic polypharmacy tended not to be
associated with elevated blood pressure, which is one of
the three criteria for metabolic syndrome, polypharmacy
may not have been correlated with metabolic syndrome,
which needs to fulfil two or more of the three criteria,
but rather with pre-metabolic syndrome, which needs to
fulfil one or more of the criteria. We speculate that anti-
psychotic polypharmacy is directly associated with meta-
bolic disturbance and increases the risk for metabolic
syndrome, but the effect on lowering blood pressure
masks the diagnosis of metabolic syndrome.
Another reason for our finding that polypharmacy
contributes in some way to metabolic syndrome is that
psychiatrists might be reluctant to prescribe additional
antipsychotics for patients with metabolic syndrome to
avoid worsening their metabolic profiles; however, for
patients with pre-metabolic syndrome, they might not
hesitate to prescribe additional antipsychotic.
Antipsychotic polypharmacy was not significantly
associated with the visceral fat obesity group. That may
be why the sample size in the group was small. We
speculate that the association between polypharmacy
and the visceral fat obesity may become significant if
the sample size is larger.
Among the lifestyle factors, smoking habit was asso-
ciated with prevalence of metabolic syndrome. It is con-
sidered to be an important risk factor for metabolic
syndrome in the general population [22,23]. The preva-
lence of smoking in schizophrenia greatly exceeds that
in the general population [24-26]. For the prevention of
metabolic syndrome, it is necessary to provide guidance
for lifestyle, such as smoking cessation advice, to
patients with schizophrenia, especially those receiving
antipsychotic polypharmacy.
The limitations of our study were a cross-sectional
design, moderate sample size, high rate of refusal to parti-
cipate in the study, and non-assessment of other psycho-
tropic drugs except antipsychotics. In addition, special
conditions were imposed on antipsychotic treatment in
Japan at the time of the study, that is, clozapine had not
yet been launched and olanzapine and quetiapine were
contraindicated for patients with diabetes or a history of
diabetes. Clozapine and olanzapine, in particular, are
known as high-risk drugs for metabolic syndrome [27].
Therefore, the above special conditions are likely to have
affected the results in this study.
Conclusions
Our study is the first attempt to clarify the relationship
between metabolic syndrome, antipsychotic polyphar-
macy, and patients’ lifestyle. The findings indicate that
Table 2 Multinomial logistic regression analyses
visceral fat obesity premetabolic syndrome metabolic syndrome
Variable AOR 95% CI AOR 95% CI AOR 95% CI
Gender (male) 7.104 2.990-16.879 6.122 2.955-12.683 3.427 1.835-6.401
Smoking habit, per day
21 or more 0.353 0.093-1.337 1.726 0.750-3.974 2.298 1.074-4.916
6 to 20 0.882 0.357-2.183 1.103 0.483-2.521 1.537 0.714-3.308
1 to 5 0.480 0.054-4.286 0.784 0.144-4.266 0.736 0.143-3.799
none (reference) 1 – 1 – 1 –
Duration of psychiatric treatment, y 1.006 0.974-1.039 0.990 0.962-1.019 1.028 1.003-1.054
Total daily dose (10 mg units) 1.011 1.003-1.019 1.007 0.999-1.015 1.005 0.998-1.012
Antipsychotic polypharmacy 1.580 0.709-3.521 2.348 1.181-4.668 1.269 0.679-2.371
The dependent variable has four categories: normal, visceral fat obesity, pre-metabolic, and metabolic syndrome. The latter three categories are compared with
the normal category.
AOR: adjusted odds ratio, CI: confidence interval
Nagelkere’s R square = 0.26.
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antipsychotic polypharmacy, compared with monother-
apy, may be independently associated with an increased
risk of having pre-metabolic syndrome, even after
adjusting for patients’ lifestyle characteristics. Despite
the fact that there is little evidence regarding the effi-
cacy of antipsychotic polypharmacy in schizophrenia
and that it is not recommended in its treatment of schi-
zophrenia, it has been common practice in the past. As
metabolic syndrome is associated with an increased risk
of cardiovascular mortality, further studies are needed to
clarify the validity and safety of antipsychotic polyphar-
macy in this patient population.
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